Steno Diabetes Center Copenhagen, Gentofte, Denmark
Novo Nordisk A/S, Måløv, Denmark.
Diabetes Care. 2019 Aug;42(8):1512-1520. doi: 10.2337/dc19-0048. Epub 2019 May 23.
Trimethylamine N-oxide (TMAO) is suggested as an independent gut microbiota-derived risk factor for cardiovascular and renal disease. We investigated associations between plasma TMAO concentrations and cardio-renal outcomes in a prospective study of individuals with type 1 diabetes.
Plasma TMAO was measured at baseline in 1,159 individuals with type 1 diabetes (58% male, mean ± SD age 46 ± 13 years). End points were all-cause and cardiovascular mortality, cardiovascular disease (CVD), and renal events tracked from national registries. Associations between TMAO and end points were tested using Cox regression models.
After 15.0 (6.7-19.3) (median [interquartile range]) years of follow-up, we recorded all-cause and cardiovascular mortality ( = 363 and 120, respectively), combined CVD ( = 406), coronary outcome (myocardial infarction and coronary intervention) ( = 163), stroke ( = 115), hospitalization for heart failure ( = 81), and end-stage renal disease ( = 144). In univariate analyses, higher TMAO concentrations were associated with all end points ( ≤ 0.005). Except for stroke and heart failure, all end points remained significantly associated with higher TMAO concentrations after adjustment for conventional cardiovascular risk factors ( ≤ 0.003). After further adjustment for baseline estimated glomerular filtration rate (eGFR), results became insignificant for all end points. TMAO was inversely associated with baseline eGFR ( = 0.29; < 0.001).
In individuals with type 1 diabetes, higher concentrations of plasma TMAO were associated with mortality, CVD events, and poor renal outcome, independent of conventional risk factors. However, the association became insignificant after further adjustment for baseline eGFR. This could reflect TMAO as a renal function marker or a risk factor for micro- and macrovascular complications mediated through impaired renal function.
三甲基胺 N-氧化物(TMAO)被认为是心血管和肾脏疾病的独立肠道微生物衍生风险因素。我们在一项对 1159 例 1 型糖尿病患者的前瞻性研究中,调查了血浆 TMAO 浓度与心肾结局之间的关系。
在 1159 例 1 型糖尿病患者(58%为男性,平均年龄 46±13 岁)中,在基线时测量了血浆 TMAO。终点是全因死亡率和心血管死亡率、心血管疾病(CVD)和从国家登记处追踪到的肾脏事件。使用 Cox 回归模型测试 TMAO 与终点之间的关系。
在 15.0(6.7-19.3)(中位数[四分位距])年的随访后,我们记录了全因死亡率和心血管死亡率(分别为 363 和 120)、复合 CVD(406)、冠状动脉事件(心肌梗死和冠状动脉介入)(163)、中风(115)、心力衰竭住院治疗(81)和终末期肾病(144)。在单变量分析中,较高的 TMAO 浓度与所有终点均相关(≤0.005)。除中风和心力衰竭外,在调整传统心血管危险因素后,所有终点与较高的 TMAO 浓度仍显著相关(≤0.003)。在进一步调整基线估算肾小球滤过率(eGFR)后,所有终点的结果均变得不显著。TMAO 与基线 eGFR 呈负相关(=0.29;<0.001)。
在 1 型糖尿病患者中,血浆 TMAO 浓度较高与死亡率、CVD 事件和不良肾脏结局相关,与传统危险因素无关。然而,在进一步调整基线 eGFR 后,这种相关性变得不显著。这可能反映了 TMAO 作为肾功能标志物或通过肾功能受损介导的微血管和大血管并发症的风险因素。